37 results on '"Mao, Xuehan"'
Search Results
2. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma
3. The impact of response kinetics for multiple myeloma in the era of novel agents
4. The age-dependent changes in risk weights of the prognostic factors for multiple myeloma
5. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
6. FIGURE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
7. TABLE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
8. Table S2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
9. TABLE 2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
10. Figure S1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
11. FIGURE 4 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
12. FIGURE 2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
13. FIGURE 3 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
14. Data from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
15. P-173 Development and validation of an individualized and weighted myeloma prognostic score system (MPSS) in patients with newly diagnosed multiple myeloma
16. Figure S2 from Clinical benefit of autologous stem cell transplantation for multiple myeloma patients achieving undetectable minimal residual disease after induction treatment
17. Table S3 from Clinical benefit of autologous stem cell transplantation for multiple myeloma patients achieving undetectable minimal residual disease after induction treatment
18. Data from Clinical benefit of autologous stem cell transplantation for multiple myeloma patients achieving undetectable minimal residual disease after induction treatment
19. Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma
20. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment
21. Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome
22. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib
23. Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma
24. 1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma
25. Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma
26. Development of a Clinical Risk Stratification for Patients with Newly Diagnosed Multiple Myeloma
27. Tolerance, kinetics and depth of response for subcutaneous versus intravenous administration of bortezomib combination in Chinese newly diagnosed multiple myeloma patients
28. The prognostic impact of dynamic changing of cytogenetic abnormalities under the treatment options in multiple myeloma
29. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma
30. IgH translocations with undefined partners are associated with superior outcome in multiple myeloma patients
31. The impact of response kinetics following initial therapy for multiple myeloma in the era of novel agents
32. Multiple high-risk cytogenetic aberrations confer a progressively negative impact on survivals of newly diagnosed myeloma patients
33. The prognostic value of 1q21 gain does not rely on the copy numbers, clone size and concurrence with t(4;14)
34. Real-world Outcomes of Chinese patients with high-risk Multiple Myeloma
35. Clinical Characteristics, Survival Outcomes and prognosis in 82 Immunoglobulin D Multiple Myeloma Patients: A Retrospective Single-Center Study
36. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib.
37. Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.